title: Separate and combined effects of caffeine and alprazolam on motor activity and benzodiazepine receptor binding in vivo.
abstract: CD-1 mice received single intraperitoneal (IP) doses of caffeine-sodium benzoate (caffeine doses: 0, 20 and 40 mg/kg) followed by injections of alprazolampropylene glycol (0, 0.05, and 2 mg/kg, IP) to determine brain concentrations, effects on in vivo receptor binding of a specific high-affinity benzodiazepine receptor ligand [3H]Ro15-1788, and effects on motor activity over a 1-h period. A behavioral monitoring device, using infrared sensors, measured horizontal and ambulatory activity. Caffeine produced significant increases in all motor activity measures as compared to vehicle treatment, with low dose caffeine (with brain concentrations of 13 micrograms/g) stimulating activity to a greater degree than the high dose (with brain concentrations of 30 micrograms/g). The overall effect of caffeine on benzodiazepine receptor binding was not significant. Alprazolam significantly diminished motor activity and altered benzodiazepine receptor binding. Low dose alprazolam increased binding, while the high dose diminished it. Caffeine and alprazolam antagonized each other's behavioral effects in this study, but did not alter each other's uptake into brain. Alprazolam's antagonism of caffeine-induced motor stimulation was associated with decreases in receptor binding, whereas caffeine's reversal of alprazolam-induced motor depression was not associated with any changes in binding. The lack of a clear association between drug effects on benzodiazepine binding and on motor activity suggests that behavioral effects of caffeine and alprazolam may be mediated by other sites in addition to the benzodiazepine receptor.
authors.affiliation: Department of Psychiatry, Tufts University School of Medicine, Boston, MA 02111.
authors.forename: G B
authors.initials: GB
authors.lastname: Kaplan
authors.forename: N T
authors.initials: NT
authors.lastname: Tai
authors.forename: D J
authors.initials: DJ
authors.lastname: Greenblatt
authors.forename: R I
authors.initials: RI
authors.lastname: Shader
mesh_terms: D000525:Alprazolam / Q000494:pharmacology*; D000818:Animals; D001923:Brain Chemistry / Q000187:drug effects; D002110:Caffeine / Q000494:pharmacology*; D002851:Chromatography, High Pressure Liquid; D004347:Drug Interactions; D005442:Flumazenil / Q000494:pharmacology; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects*; D011963:Receptors, GABA-A / Q000187:drug effects / Q000378:metabolism*; D014970:Xanthines / Q000302:isolation & purification
chemical_list: D011963:Receptors, GABA-A; D014970:Xanthines; D002110:Caffeine; D005442:Flumazenil; D000525:Alprazolam